Antiviral monoclonal antibodies
- Name
- Antiviral monoclonal antibodies
- Accession Number
- DBCAT005730
- Description
Not Available
- ATC Classification
- Drugs
Drug Drug Description Palivizumab A monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients. Motavizumab Investigated for use/treatment in viral infection and pediatric indications. Cilgavimab An extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization. Tixagevimab An extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization. Imdevimab Part of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19. Casirivimab Part of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19. Nirsevimab A long-acting monoclonal antibody indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. Sotrovimab A monoclonal antibody for the treatment of mild-to-moderate COVID-19 in patients at increased risk for death or hospitalization. Ansuvimab A fully human monoclonal IgG1 antibody directed against the GP1,2 surface protein of Zaire ebolavirus that is an effective treatment for Ebola virus disease. Regdanvimab A monoclonal antibody targeted against the SARS-CoV-2 spike protein used to treat patients with COVID-19 who are at risk of progressing to severe COVID-19. - Drugs & Drug Targets